Immune checkpoint inhibitors plus chemotherapy in the first-line treatment of young unresectable gastric cancer patients: a multicentre real-world study
Young patients with GC have unique clinical characteristics and are not sensitive to immunotherapy. Triple regimens, especially intraperitoneal infusion of paclitaxel followed by intravenous paclitaxel combined with S-1 and apatinib oral therapy, deserve to be studied as first-line therapies.
Authors
- Yan Li (ORCID: https://orcid.org/0000-0003-3153-6396)
- Zhanjun Guo (ORCID: https://orcid.org/0000-0002-5111-5444)
- Hongmei Xu (ORCID: https://orcid.org/0000-0002-8650-8694)
- Yingnan Wang (ORCID: https://orcid.org/0000-0001-7138-7204)
- Zheng Liu (ORCID: https://orcid.org/0000-0002-7241-3483)
- Fengbin Zhang (ORCID: https://orcid.org/0000-0003-4041-8770)
- Ruixing Zhang (ORCID: https://orcid.org/0000-0001-7341-0631)
- Jing Liu (ORCID: https://orcid.org/0009-0008-2772-0418)
Institutions
- Hebei Medical University (CN)
- Handan College (CN)
- Fourth Hospital of Hebei Medical University (CN)
- First Hospital of Qinhuangdao (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-11
- DOI
- https://doi.org/10.3389/fonc.2025.1476402
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.52